Anterior
0%
est. 2Y upside i
Anterior is the clinical AI platform built specifically for payers. We sit at the unique intersection of clinician expertise, explainable intelligence, and partner-driven deployment.
Rank
#2138
Sector
Healthcare AI, Digital Health
Est. Liquidity
~5Y
Data Quality
Data: LowThis is a high-risk, high-reward opportunity with severe data gaps.
Last updated: July 19, 2026
Healthcare AI adoption accelerates; Anterior's partnerships with Geisinger and HealthEdge drive revenue growth, but actual revenue unknown, so upside is speculative.
Moderate growth with enterprise SaaS expansion; revenue could double but preference overhang dilutes common stock returns.
Competition from Cohere Health or incumbents limits traction; exit below $64M results in zero recovery for common stock due to preferred liquidation preference.
Preference Stack Risk
severeFunding Intensity
6740%Total funding of $64M on a $95M valuation (67% preferred) means common stock is subordinate to a large liquidation preference.
Dilution Risk
highLikely need additional capital within 24 months given early stage and 46 employees; further rounds will dilute common equity.
Secondary Liquidity
noneNo secondary market transactions reported; private stock is illiquid until a liquidity event.
Engineering — 1 role
- Member of Technical Staff · New York
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on Anterior's data — designed to show you've done your homework.
- 1
“What is Anterior's current annual recurring revenue and net dollar retention?”
- 2
“How does Anterior's AI agent differentiate from Cohere Health's solution?”
- 3
“What is the expected timeline for an IPO or acquisition, and how does that align with employee equity liquidity?”
Community
Valuation Sentiment
Our model estimates 0% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.